---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-177015"
form_type: "8-K"
ticker: "PRGO"
cik: "0001585364"
company_name: "PERRIGO Co plc"
filed_at: "2024-07-10T23:59:59+00:00"
generated_at: "2026-05-31T22:08:01.439233+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Perrigo completes divestiture of HRA Pharma Rare Diseases to Esteve for up to €275M

## Summary
- Total consideration up to €275M: €190M upfront cash plus up to €85M in earnout based on sales milestones.
- Proceeds to be redeployed for debt repayment; impact included in previously issued 2024 outlook.
- Rare Diseases business had FY2023 net sales of ~€50M and adjusted EBITDA of ~€20M.

## SEC filing metadata
- accession: 0001193125-24-177015
- form_type: 8-K
- ticker: PRGO
- cik: 0001585364
- company_name: PERRIGO Co plc
- filed_at: 2024-07-10T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1585364/000119312524177015/0001193125-24-177015-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1585364/000119312524177015/d846136d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-177015
- JSON: https://secwatch.observer/filing/0001193125-24-177015.json
- Plain text: https://secwatch.observer/filing/0001193125-24-177015.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.